Tolerability and Benefit of IQP-AS-121 on Fatigue and Mental Alertness

NCT02871271 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2020-02-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the tolerability and benefit of IQP-AS-121 on reducing fatigue and tiredness and to improve mental alertness.

Conditions

Interventions

DIETARY_SUPPLEMENT

IQP-AS-121

Sponsors & Collaborators

  • InQpharm Group

    lead INDUSTRY

Principal Investigators

  • Ralf Uebelhack,, MD, PhD · analyze & realize GmbH

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-03-31
Completion
2017-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02871271 on ClinicalTrials.gov